Strategy of liver-directed gene therapy: Present status and future prospects

Liver

Volumn 19, Issue 4, 1999, Pages 265-274

  Shiratori, Yasushi ^a   Kanai, Fumihiko ^a   Ohashi, Makoto ^a   Omata, Masao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Cell specific gene transfer; Gene switch; Gene therapy; Tissue specific gene transfer; Transcriptional regulation; Transcriptional targeting

Indexed keywords

ANTIVIRUS AGENT;

ADENOVIRUS; ANTINEOPLASTIC ACTIVITY; DRUG DELIVERY SYSTEM; FUTUROLOGY; GENE EXPRESSION; GENE SWITCHING; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC DISORDER; GENETIC ENGINEERING; GENETIC TRANSCRIPTION; GENETIC TRANSFECTION; GENETICS; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LIVER CANCER; LIVER DISEASE; METABOLIC DISORDER; REVIEW; TARGET CELL; TRANSGENE;

ANIMALS; GENE THERAPY; GENE TRANSFER TECHNIQUES; HUMANS; LIVER DISEASES; PRACTICE GUIDELINES; TREATMENT OUTCOME;

EID: 0032767241     PISSN: 01069543     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1478-3231.1999.tb00048.x     Document Type: Review

References (83)

1. ROEMER K, FRIEDMANN T. Concepts and strategies for human gene therapy. Eur J Biochem 1992; 208: 211-25.
2. CHANG A Y, WU G Y. Gene therapy: applications to the treatment for gastrointestinal and liver diseases. Gastroenterology 1994; 106: 1076-84.
3. ALT M, CASELMANN W F. Liver-directed gene therapy: molecular tools and recurrent pre-clinical and clinical studies. J Hepatol 1995; 23: 746-58.
4. STRAUSS M. Liver-directed gene therapy: prospective and problems. Gene Therapy 1994; 1: 156-64.
5. ZERN M A, KRESINA T F. Hepatic drug delivery and gene therapy. Hepatology 1997; 25: 484-91.
6. CRYSTAL R G. Transfer of genes to human: early lessons and obstacles to success. Science 1995; 270: 404-10.
7. FERRY N, HEARD J M. Liver-directed gene transfer vectors. Hum Gene Ther 1998; 9: 1975-81.
8. GUTIERREZ A A, LEMOINE N R, SIKORA K. Gene therapy for cancer. Lancet 1992; 339: 715-21.
9. GORE M E, COLLINS M K. Gene therapy for cancer. Eur J Cancer 1994; 30: 1047-9.
10. KMIEC E B. Genomic targeting and genetic conversion in cancer therapy. Semin Oncol 1996; 23: 188-93.
11. ALINO S F, BOBADILLA M, CRESPO J, LEJARRETA M. Human alpha 1-antitrypsin gene transfer to in vivo mouse hepatocytes. Hum Gene Ther 1996; 7: 531-6.
12. KAY M A, GRAHAM F, LELAND F, WOO S L C. Therapeutic serum concentrations of human alpha-1-antitrypsin after adenoviral-mediated gene transfer into mouse hepatocytes. Hepatology 1995; 21: 815-9.
13. KAY M A, ROTHENBERG S, LANDEN C N, et al. In vivo gene therapy of hemophilia B-sustained partial correction in factor IX-deficient dogs. Science 1993; 262: 117-9.
14. KOEBERL D D, ALEXANDER L E, HALBERT C L, RUSSELL D W, MILLER A D. Persistent expression of human clotting factor IX from mouse liver after intravenous injection of adeno-associated virus vectors. Proc Natl Acad Sci U S A 1997; 94: 1426-31.
15. OVERTURF K, ALDHALIMY M, OU C N, et al. Adenovirus-mediated gene therapy in a mouse model of hereditary tyrosinemia type I. Hum Gene Ther 1997; 8: 513-21.
16. OVERTURE K, ALDHALIMY M, TANGUAY R, et al. Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinemia type I. Nat Genet 1996; 12: 266-73.
17. YE X H, ROBINSON M B, BATSHAW M L, FURTH E E, SMITH I, WILSON J M. Prolonged metabolic correction in adult ornithine transcarbamylase-deficient mice with adenoviral vectors. J Biol Chem 1996; 271: 3639-46.
18. FANG B, EISENSMITH R C, LI X H, FINEGOLD M J, WOO S L. Gene therapy for phenylketonuria: phenotypic correction in a genetically deficient mouse model by adenovirus-mediated hepatic gene transfer. Gene Ther 1994; 4: 247-54.
19. SEPPEN J, TADA K, OTTENHOFF R, SENGUPTA K, CHOWDHURY N R, CHOWDHURY J R. Transplantation of Gunn rats with autologous fibroblasts expressing bilirubin UDP-glucuronosyltransferase: correction of genetic deficiency and tumor formation. Hum Gene Ther 1997; 8: 27-35.
20. QIANHONG L, MURPFREE S S, WILLER S S, BOLLI R, FRENCH B A. Gene therapy with bilirubin UDP-glucuronosyltransferase in the Gunn rat model of Crigler-Najjar syndrome type I. Hum Gene Ther 1998; 9: 497-505.
21. GROSSMAN M, RAPER S E, KOZARSKY K, et al. Successful ex vivo gene therapy directed to liver in a patient with familiar hypercholesterolaemia. Nat Genet 1994; 6: 335-41.
22. GROSSMAN M, RADER D J, MULLER D, et al. A pilot study of ex vivo gene therapy for homozygous familiar hypercholesterolemia. Nat Med 1995; 1: 1148-54.
23. VON WEIZSACKER F, WIELAND S, KOCK J, et al. Gene therapy for chronic viral hepatitis: ribozymes, antisense oligonucleotides, and dominant negative mutants. Hepatology 1997; 26: 251-5.
24. SHIRATORI Y, KANAI F, HAMADA H, et al. Gene therapy for hepatic micrometastasis of murine colon carcinoma. J Hepatol 1998; 28: 886-95.
25. CARSO M, PHAM-NGUYEN K, KWONG Y L, et al. Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci USA 1996; 93: 11302-6.
26. CHEN S H, CHEN X H L, WANG Y, KOSAI K, FINEGOLD M J, RICH S S, WOO S L C. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci U S A 1995; 92: 2577-81.
27. KANAI F, SHIRATORI Y, YOSHIDA Y, et al. Gene therapy for alpha-fetoprotein-producing human hepatoma cells by adenovirus-mediated transfer of the herpes simplex thymidine kinase gene. Hepatology 1996; 23: 1359-68.
28. KANEKO S, HALLENBECK P, NAKABAYASHI H, et al. Adenovirus-mediated gene therapy of hepatocellular carcinoma using cancer-specific gene expression. Cancer Res 1995; 55: 5283-7.
29. WU G Y, WU C H. Receptor-mediated gene delivery and expression in vivo. J Biol Chem 1988; 263: 14621-4.
30. CHIOU H C, TANGCO M V, LEVINE S M, et al. Enhanced resistance to nuclease degradation of nucleic acids complexed to asialoglycoprotein-polylysine carriers. Nucleic Acids Res 1994; 22: 5439-46.
31. ERBACHER P, ROCHE A C, MONSIGNY M, MIDOUX P. Putative role of chloroquine in gene transfer into a human hepatoma cell line by DNA lactosylated polylysine complex. Exp Cell Res 1996; 225: 186-94.
32. PERALES J C, FERKOL T, BEEGEN H. RATNOFF O D, HANSON R W. Gene transfer in vivo-sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 1994; 92: 4086-90.
33. HARA T, TAN Y, HUANG L. In vivo gene delivery to the liver using reconstituted chylomicron remnants as a novel non viral vector. Proc Natl Acad Sci USA 1997; 94: 14547-52.
34. REMY J S, KICHLER A, MORDVINOV V, SCHUBER F, BEHR J P. Targeted gene transfer into hepatoma cells with lipopolyamine-condensed DNA particles presenting galactose ligand: a stage toward artificial viruses. Proc Natl Acad Sci USA 1995; 92: 1744-8.
35. KASAHARA N, DOZY A M, KAN Y W. Tissue-specific targeting of retro viral vectors through ligand-receptor interaction. Science 1994; 266: 1373-5.
36. CRISTIANO R J, SMITH L C, WOO S L C. Hepatic gene therapy -adenovirus enhancement of receptor-mediated gene delivery and expression in primary hepatocytes. Proc Natl Acad Sci USA 1993; 90: 2122-6.
37. JAFFE H A, DANEL C, LONGENECKER G, METZGER M, SETOGUCHI Y, ROSENFELD M A. Aderiovirus-mediated in vivo gene transfer and expression in normal rat liver. Nat Genet 1992; 1: 372-8.
38. KASS-EISLER A, FALCK-PEDERSEN E, ELFENBEIN D H, ALVIRA M, BUTTRICK P M, LEINWAND L A. The impact of developmental stage, route of administration and the immune system on adenovirus-mediated gene transfer. Gene Ther 1994; 1: 395-402.
39. ILAN Y, JONA V K, SENGUPTA K, et al. Transient immuno-suppression with FK506 permits long-term expression of therapeutic genes introduced into the liver using recombinant adenoviral vectors. J Clin Invest 1997; 99: 1098-106.
40. WORGALL S, WOLFF G, FALCK-PEDERSEN E, CRYSTAL R G. Innate immune mechanisms dominate elimination of adenoviral vectors following in vivo administration. Hum Gene Ther 1997; 8: 37-44.
41. JOOSS K, YANG Y, WILSON J M. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung. Hum Gene Ther 1996; 7: 1555-66.
42. SCHIEDNER G, MORRAL N, PARKS R J, WU Y, KOOPMANS S C, LANGSTON C. Genomic DNA transfer with a high capacity adenovirus vector results in improved in vivo expression and decreased toxicity. Nature Genet 1998; 18: 180-3.
43. SNYDER R O, MIAO C H, PATUN G A, SPRATT S K, DANOS O, NAGY D. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-6.
44. BUDKER V, ZHANG G, KNECHTLE S, WOLFF J. Naked DNA delivered intraportally expresses efficiently in hepatocytes. Gene Ther 1996; 3: 593-8.
45. ZHANG G, VARGO D, BUDKER V, ARMSTRONG N, KNECHTLE S, WOLFF J. Expression of naked plasmid DNA injected into afferent and efferent vessels of rodents and dog liver. Hum Gene Ther 1997; 8: 1763-72.
46. ARMENTANO D, TGHOMPSON A R, DARLINGTON G, WOO S L. Expression of human factor IX in rabbit hepatocytes by retrovirus mediated gene transfer: potential for gene therapy to hemophilia B. Proc Natl Acad Sci USA 1990; 87: 6141-5.
47. LE M, OKUYAMA T, CAI S R, KENNEDY S C, BOWLING W M, FLYE M W, PONDER K P. Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy. Blood 1997; 89: 1254-9.
48. CRISTIANO R J, DSMITH L C, KAY M A, BRINKLEY B R, WOO S L C. Hepatic gene therapy: efficient gene delivery and expression in primary hepatocytes utilizing a conjugated adenovirus-DNA complex. Proc Natl Acad Sci USA 1993; 90: 11548-52.
49. MILLER N, WHELAN J. Progress in transcriptionally targeted and regulatable vectors for genetic therapy. Hum Gene Ther 1997; 8: 803-15.
50. FARHOOD H, GAO X, BARSOUM J, HUANG L. Codelivery to mammalian cells of a transcriptional factor with cis-acting element using cationic liposomes. Anal Biochem 1995; 225: 89-93.
51. HAUCK W, STANNERS C P. Transcriptional regulation of the carcinoembryonic antigen gene. J Biol Chem 1995; 270: 3602-10.
52. LAN K H, KANAI F, SHIARTORI Y, OKABE S, YOSHIDA Y, WAKIMOTO H. Tumor-specific gene expression in carcinoembryonic antigen-producing gastric cancer cells using adenovirus vectors. Gastroenterology 1996; 111: 1241-51.
53. TANAKA T, KANAI F, LAN K H, OHASHI M, SHIRATORI Y, YOSHIDA Y. Adenovirus mediated gene therapy of gastric carcinoma using cancer specific gene expression in vivo. Biochem Biophys Res Commun 1997; 231: 775-9.
54. LAN K H, KANAI F, SHIRATORI Y, et al. In vivo selective gene expression and therapy mediated by adenoviral vector for human carcinoembryonic antigen-producing gastric carcinoma. Cancer Res 1997; 57: 4279-84.
55. OHASHI M, KANAI F, TANAKA T, LAN KH, SHIRATORI Y, KOMATSU Y. In-vivo adenovirus-mediated prodrug gene therapy for carcinoembryonic antigen-producing pancreatic cancer. Jpn J Cancer Res 1998; 89: 457-62.
56. KANAI F, KAWAKAMI T, HAMADA H, et al. Adenovirus-mediated transduction of Escherichia coli uracil phosphoribosyltransferase gene sensitizes cancer cells to low concentrations of 5-fluorouracil. Cancer Res 1998; 58: 1946-51.
57. AIRD W C, JAHROUDI N, WEILER-GUETTLER H, RAY-BURN H B, ROSENBERG R D. Human von Willebrand factor gene sequences target expression to a subpopulation of endothelial cells in transgenic mice. Proc Natl Acad Sci U S A 1995; 92: 4567-71.
58. OZAKI K, YOSHIDA T, IDE H, et al. Use of von Willebrand factor promoter to transduce suicidal gene to human endothelial cells, HUVEC. Hum Gene Ther 1996; 7: 1483-90.
59. HARATS D, KURIHARA H, BELLONI P, et al. Targeting gene expression to the vascular wall in transgenic mice using the murine preproendothelin promoter. J Clin Invest 1995; 95: 1335-44.
60. MORISHITA K, JOHNSON D E, WILLIAMS L T. A novel promoter for vascular endothelial growth factor receptor (flt-1) that confers endothelial-speciflc gene expression. J Biol Chem 1995; 270: 27948-53.
61. PELEGRIN M, MARIN M, NOEL D, PIECHACZYK M. Genetically engineered antibodies in gene transfer and gene therapy. Hum Gene Ther 1998; 9: 2165-75.
62. DOUGLAS J T, ROGERS B E, ROSENFELD M E, MICHAEL S I, FENG M, CURIEL D T. Targeted gene delivery by tropism-modified adenoviral vectors. Nat Biotechnol 1996; 14: 1574-8.
63. WICHAM T J, SEGAL D M, ROELVINK P W, et al. Targeted adenovirus gene transfer to endothelial and smooth muscle cells by using bispecific antibodies. J Virol 1996; 70: 6831-8.
64. GOSSEN M, FREUNLIEB S, BENDER G, MULLER G, HILLEN W, BUJARD H. Transcriptional activation by tetracycline in mammalian cells. Science 1995; 268: 1766-9.
65. SHOKETT P, DIFILIPPANTONIO M, HELLMAN N, SCHATZ D G. A modified tetracycline-regulated system provides autoregulatory, inducible gene expression in cultured cells and transgenic mice. Proc Natl Acad Sci USA 1995; 92: 6522-6.
66. FURTH P A, ONGE L, BOGER H, et al. Temporal control of gene expression in transgenic mice by a tetracycline-responsive promoter. Proc Natl Acad Sci USA 1994; 91: 9302-6.
67. BARON U, FREUDLIEB S, GOSSEN M, BUJARD H. Co-regulation of two gene activities by tetracycline via a bidirectional promoter. Nucleic Acids Res 1995; 23: 3605-6.
68. PAILLARD F. "Tet-on": A gene switch for exogenous regulation of transgene expression. Commentary. Hum Gene Ther 1998; 9: 983-5.
69. BIOULAC-SAGE P, BALABAUD C, eds. The role of hepatic sinusoidal cells in liver disease. Seminars in Liver Disease 1993; 13: 1-100.
70. PINZANI M, MARRA F, CARLONI V. Signal transduction in hepatic stellate cells. Liver 1998; 18: 2-13.
71. SHIRATORI Y, NAKATA R, OKANO K, et al. Inhibition of hepatic metastasis of colon carcinoma by asialo GM1-positive cells in the liver. Hepatology 1992; 16: 469-78.
72. SHIRATORI Y, KANAI F, HAMADA H, MORIYAMA H, HIKIBA Y, OTSUKA T. Gene therapy for hepatic micrometastasis of colon carcinoma. In: Wisse E, Knook D L, Balabaud C, eds. Cells of the hepatic sinusoid. vol. 6, Kupffer cell foundation, Leiden, 1997: 418-21.
73. GANSBACHER B, ZIER K, DANIELS B, CRONIN K, BANNERJI R, GILBOA E. Interleukin 2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 72: 1217-24.
74. BRUNDA M J, LUISTRO L, WARRIER R R, et al. Antitumor and antimetastatic activity of interleukin 12 against murine tumors. J Exp Med 1993; 178: 1223-30.
75. ROSENTHAL F M, CRONIN K, BANNERIJI R, GOLDE D W, GANSBACHER B. Augmentation of antitumor immunity by tumor cells transducted with a retroviral vector carrying the interleukin-2 and interferon-gamma cDNA. Blood 1994; 38: 1289-98.
76. VAGLIANI M, RODOFO M, CAVALLO F, PARENZA M, MELANI C, PARMIANI G. Interleukin 12 promotes the curative effect of a vaccine based on interleukin 2-transducted tumor cells. Cancer Res 1996; 56: 467-70.
77. BRAMSON J, HITT M, GALLICHAN W S, ROSENTHAL K L, GAULDIE J, GRAHAM F L. Construction of a double recombinant adenovirus vector expressing a heterodimeric cytokine: in vitro and in vivo production of biologically active interleukin-12. Hum Gene Therapy 1996; 7: 333-42.
78. MILLAUER B, SHAWVER L K, PLATE K H, RISAU W, ULLRICH A. Glioblastoma growth inhibited in vivo by a dominant-negative Flk-1 mutant. Nature 1994; 367: 576-9.
79. FAN T P, JAGGAR R, BICKNELL R. Controlling the vasculature: angiogenesis, anti-angiogenesis and vascular targeting of gene therapy. Trends Pharmacol Sci 1995; 16: 57-66.
80. SALEH M, STACHER S A, WILKS A F. Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 1996; 56: 393-401.
81. ANDREOLETTI M, PAGES J C, MAHIEU D, LOUX N, FARGE D, SACQUIN P. Preclinical studies for cell transplantation: isolation of primate fetal hepatocytes, their cryopreservation, and efficient retroviral transducticn. Hum Gene Ther 1997; 8: 267-74.
82. SIGAL S H, BRILL S, FIORINO A, REID L M. The liver as a stem cell and lineage system. Am J Physiol 1992; 263: G139-48.
83. SIGNAL S H, BRILL S, REID L M, Characterization and enrichment of fetal rat hepatoblasts by immunoadsorbtion and fluorescence-activated cell sorting. Hepatology 1994; 19: 999-1006.